Complete Story
03/20/2026
[Duplicate] Recent Oncology Related FDA Approvals and Expanded Indications
FDA Approves AstraZeneca's new treatment regimen for Calquence (acalabrutinib) in combination with Venetoclax for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
FDA Approves Boehringer Ingleheim's HERNEXEOS (zongertinib tablets), for adults with HER2-mutant advanced NSCLC as an initial treatment option
More InfoReport Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
